Document is current
Any future updates will be listed below
-
Authors
Riedl, Marc A.
Cohn, Danny M.
Magerl, Markus
Farkas, Henriette
Aygören-Pürsün, Emel
Banerji, Aleena
Bernstein, Jonathan A.
Schmaier, Alvin H.
Pardali, Evangelia
Lesage, Anne
Lu, Peng
Newby, David E.
-
Funding
Funding for this research was provided by:
Individual authors did not receive funding specifically for this manuscript, but the manuscript editing was funded by Pharvaris
- License Information
-
More Information
Article History
Received: 17 April 2026
Accepted: 14 June 2026
First Online: 3 July 2026
Declarations
:
: No new studies were performed as part of this review.
: No informed consent was required for this manuscript.
: M.A.R.: has received research grant support, consultancy fees, speaker fees, and/or clinical trial fees from Astria, BioCryst, BioMarin, Celldex, CSL Behring, Cycle Pharma, Grifols, Intellia, Ionis, KalVista, Novartis, Pharming, Pharvaris, Sanofi-Regeneron, Takeda. D.M.C.: has received consultancy fees from Astria, BioCryst, CSL Behring, Ionis, Intellia, KalVista, Otsuka, Pharvaris, Takeda; speaking fees from CSL Behring, Ionis, Takeda. M.M.: has received research grant support and/or speaker/consultancy fees from or is/was investigator in clinical studies for Astria, BioCryst, CSL Behring, Intellia, KalVista, Novartis, Octapharma, Otsuka, Pharvaris, Takeda. H.F.: has received research grants from CSL Behring, Pharming, Takeda and served as an advisor for these companies and BioCryst, Intellia, KalVista, ONO Pharmaceutical, Pharvaris; has participated in clinical trials/registries for BioCryst, CSL Behring, KalVista, Pharming, Pharvaris, Takeda. E.A.-P.: has received fees as a speaker and/or consultant from Astria, BioCryst, BioMarin, CSL Behring, Intellia, KalVista, Otsuka, Pharming, Pharvaris, Takeda; grants from CSL Behring, Takeda. A.B.: has received research funding from Ionis, Astria, and Intellia, and advisory boards with CSL Behring, Ionis, Pharvaris, Intellia, KalVista, Astria, Takeda. J.A.B.: is a consultant and principal investigator for BioCryst, BioMarin, CSL Behring, Intellia, Ionis, KalVista Pharmaceuticals, Pharming, and Takeda/Shire; and is a consultant for Astria, Cycle Pharmaceuticals, and ONO Pharmaceutical. A.H.S.: Grant/research support/funding from the National Institutes of Health and Shire (a Takeda Company); consultancy for Merck; data safety management board for Intellia; scientific advisory board for Rezolute. E.P.: employee of Pharvaris, holds stocks/stock options in Pharvaris. A.L.: employee of GrayMatters Consulting and consultant to Pharvaris, holds stocks/stock options in Pharvaris; advisor to Kosa Pharma. P.L.: employee of Pharvaris and holds stock in Pharvaris. D.E.N.: institutional research grants from the British Heart Foundation (CH/09/002, RG/F/22/110093, and RE/24/130012).
